Frederique Menzaghi Ph.D., Chief Scientific Officer, SVP-R&D at Cara Therapeutics, Inc. (CARA), sold 3,506 shares at $11.27 ($40K) on 2022-12-21, disclosed to the SEC on 2022-12-23.
Scheduled sale ($40k) by Chief Scientific Officer, SVP-R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CARA | SELL | 2023-03-07 | $132K | — | Filing → |
| CARA | SELL | 2022-04-05 | $21K | — | Filing → |
| CARA | SELL | 2022-03-01 | $22K | — | Filing → |